Nonalcoholic steatohepatitis (NASH)
Nonalcoholic steatohepatitis (NASH) affects individuals slowly and progressively. Presently, there exists no FDA-approved drugs and NASH treatment landscape guides for lifestyle modifications and other non-curative options.
With the end goal to halt or reverse the hepatic fibrosis associated with NASH, several pharmaceutical companies are exploring novel disease-modifying drugs. However, the NASH therapy market is infamous due to the number of failures of drugs that seemed potential in the earlier stages of clinical development.
Even so, the NASH drug market continues to attract pharma and biotech companies despite the treacherous fate of previous drugs leading to intense competition.
Get access to the newsletter and learn more about the pipeline drugs expected to enter the market, their efficacy and potential, along with challenges in the growth of the Nonalcoholic steatohepatitis market size growth.
The newsletter outlines a complete picture of the Nonalcoholic steatohepatitis market landscape, pipeline therapies, clinical trials, NASH epidemiological insights, prevalence/ incidence, recent happenings in the NASH market domain, mergers and collaborations, licensing deals along with the conferences expected in the near future.
Subscribe to our mailing list and stay up-to-date with all the recent breakthroughs in the Pharma and Healthcare market.
Know more about What's covered:
- Indication overview
- Epidemiological trends
- Treatment approaches
- Clinical trials
- Pipeline drugs
- News
- R&D in the field
- Support from International organizations
- Market insights
- Market Drivers & Barriers
- Unmet needs
